Coexistence HBsAg/HBcAC, Clinical Characterístics & Outcomes

Characteristics of Hepatitis B HBsAg & HBsAc Carriers Simultaneously

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT05446532

Enrollment

120

Registered

2022-07-06

Start date

2022-06-15

Completion date

2022-12-31

Last updated

2025-05-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hepatitis B

Brief summary

HBV infection is a dynamic process with complex interactions between virus replication and the host's immune response. The appearance of anti-HBs after HBV infection generally indicates recovery and immunity to HBV1 infection. However, there are several published studies that describe the coexistence of the marker of chronic infection (HBsAg +) and the marker of functional cure (HBsAc +). There are contradictory studies on whether the coexistence of HBsAg/HBsAc implies a different clinical course.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 90 Years

Healthy volunteers

Inclusion criteria

* all those patients who have been seen in outpatient hepatology consultations and who present positive HBsAg and HBsAc serology simultaneously.

Exclusion criteria

* Hepatitis C or HIV Co-infection

Design outcomes

Primary

Measure	Time frame	Description
prevalence concomitant HBsAg and HBsAc markers	10 years	To describe the prevalence of concomitant HBsAg and HBsAc markers in our area

Secondary

Measure	Time frame	Description
differences between immunocompetent patients with respect to immunocompromised ones.	10 years	To compare if there are differences in the prevalence or clinical outcome according if the patient has any degree of immunosupresion or not.

Countries

Spain

Outcome results